Perritt Capital Management’s Trinity Biotech TRIB Stock Holding History

Perritt Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-384	Closed	-$761K	–	229
2016 Q3	$761K	Sell	384 -3	-0.8%	-$5.6K	0.19%	117
2016 Q2	$659K	Buy	387 +22	+6%	+$37.2K	0.17%	125
2016 Q1	$638K	Buy	365 +13	+4%	+$20.7K	0.16%	134
2015 Q4	$621K	Sell	352 -1,460	-81%	-$2.59M	0.13%	143
2015 Q3	$3.11M	Buy	1,812 +108	+6%	+$261K	0.65%	67
2015 Q2	$4.62M	Sell	1,704 -1	-0.1%	-$2.6K	0.82%	38
2015 Q1	$4.92M	Sell	1,705 -1	-0.1%	-$2.77K	0.87%	32
2014 Q4	$4.48M	Buy	1,706 +1,469	+620%	+$3.8M	0.82%	41
2014 Q3	$649K	Sell	237 -3	-1%	-$9.75K	0.12%	167
2014 Q2	$829K	Sell	240 -31	-11%	-$110K	0.14%	156
2014 Q1	$984K	Sell	271 -62	-19%	-$244K	0.16%	140
2013 Q4	$1.26M	Hold	333	–	–	0.21%	123
2013 Q3	$1.09M	Hold	333	–	–	0.21%	116
2013 Q2	$842K	Buy	+333	New	+$829K	0.19%	119

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

SCM

Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Perritt Capital Management's TRIB Position: Q4 2016 in Review

Perritt Capital Management sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 384 shares — an estimated $761K sold.

Perritt Capital Management first reported a position in TRIB in Q2 2013 and held it in 14 quarters. The position peaked at $4.92M in Q1 2015. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

Perritt Capital Management reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
Perritt Capital Management sold 384 Trinity Biotech shares in Q4 2016, an estimated $761K.
Perritt Capital Management first reported a position in Trinity Biotech in Q2 2013 and held it in 14 quarters.
Perritt Capital Management's Trinity Biotech position peaked at $4.92M in Q1 2015.
71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Perritt Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.